“While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis,” CEO Stephane Bancel said in a statement. Bancel noted that Moderna would “explore alternatives” to continue funding for the new vaccine, reported AFP.

Robert F. Kennedy Jr.’s Make America Healthy Again Commission will assess the causes of childhood disease on Thursday.